Pulmonx Corp 8-K Summary (October 5, 2020)
Business Context and Reporting Period
This Form 8-K was filed by Pulmonx Corporation on October 5, 2020, to report corporate governance actions taken in connection with the closing of its initial public offering (IPO). The company is incorporated in Delaware and trades on The Nasdaq Stock Market under the symbol "LUNG".
Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on legal and corporate structural updates rather than financial performance data.
Material Changes
- Amended and Restated Certificate of Incorporation: Filed with the Delaware Secretary of State on October 5, 2020, effective upon the closing of the IPO.
- Amended and Restated Bylaws: Became effective on October 5, 2020, in connection with the IPO closing.
- Capital Structure: The company now has Common Stock with a $0.001 par value registered under Section 12(b) of the Exchange Act.
Guidance, Outlook, and Risks
The filing does not contain management guidance, financial outlook, risk factors, or contingencies. It references the final prospectus filed on October 1, 2020, for a detailed description of the capital stock and related terms.
Key Facts for Investor Verification
- Verify the terms of the Amended and Restated Certificate of Incorporation (Exhibit 3.1) and Bylaws (Exhibit 3.2) attached to this filing.
- Review the final prospectus filed on October 1, 2020 (File No. 333-248635) for details on the IPO pricing, share count, and use of proceeds.
- Confirm the company's status as an emerging growth company, as indicated by the checkmark in the filing.